|
|
Survival
with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
Fazeny-Dorner
B, Veitl M, Wenzel C, Rossler K, Ungersbock K, Dieckmann K, Piribauer M,
Hainfellner J, Marosi C
Clinical Division of
Oncology and Ludwig Boltzmann Institute for Clinical and Experimental Oncology,
Department of Internal Medicine I, University of Vienna, Austria. barbara.doerner@chello.at.
A total
of 55 patients with histologically proven glioblastoma multiforme (total gross
resection: n=24, subtotal resection: n=20, stereotactic biopsy: n=11) were
treated with the combination of dacarbazine (D) (200 mg m(-2)) and fotemustine
(F) (100 mg m(-2)) and concomitant radiotherapy (2 Gy day(-1), 5 days per week
using limited fields up to 60 Gy) to assess efficacy and toxicity of this
regimen.
Survival (median survival, 12-, 18- and 24-month survival rates) and time to
progression (median time to progression (TTP), 6-month progression-free
survival) were analysed by Kaplan-Meier's method.
A total of 268 (range 1-8, median: 5) cycles were administered.
Median survival is 14.5+ (range: 0.5-40+) months, and the 12-, 18- and 24-month
survival rates are 58, 29 and 23%, respectively.
Median TTP from the start of D/F therapy is 9.5+ (range: 0.5-33+) months.
The 6-month progression-free survival is 54%.
Partial remissions were observed in 3.6%.
Main toxicity was thrombocytopenia.
Five patients were excluded from further D/F application, four patients because
of prolonged thrombocytopenia NCI-CTC grades 3 and 4 and one patient because of
whole body erythrodermia.
One patient died because of septic fever during thrombocytopenia and leukopenia
NCI-CTC grade 4 after the first cycle.
No other toxicities of NCI-CTC grade 3 or 4 occurred.
The treatment is feasible in a complete outpatient setting and the results of
the D/F regimen justify further investigations with these compounds.
PMID:
12592361 [PubMed - in process]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12592361&dopt=Abstract
|
